GW regains US rights to Sativex

14th December 2017 Uncategorised 0

GW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka.

More: GW regains US rights to Sativex
Source: News